Effectiveness of acupuncture for anxiety and depression in irritable bowel syndrome
A protocol for systematic review and meta-analysis

Huayu Li, MMa, Yun Chen, MMb, Ziyi Hu, PhDc, Jiawang Jiang, MMd, Jing Ye, PhDd,e, Yuliang Zhou, MMA, Zhiying Yu, MMA, Haiyi Tang, MMA

Abstract

Background: Irritable bowel syndrome (IBS) is the most commonly gastrointestinal diseases. The Rome Foundation’s global study on 33 countries shows the total prevalence of IBS under the Rome IV Diagnostic Criteria was 3.8%. It is well established that people with IBS have higher levels of anxiety and depression. The impact of the acupuncture associated with anxiety and depression has been widely studied in Western countries. Acupuncture may be a promising choice for the treatment of anxiety and depression in IBS.

Methods: RCTs of acupuncture for depression and anxiety in IBS will be searched in the relevant database, including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), and Chinese Scientific Journal Database (VIP database). The studies of electronic searches will be exported to EndNote V.9.1 software. We will run meta-analyses using the Review Manager (RevMan) V.5.3 software. Any disagreement will be solved in consultation with a third reviewer.

Results: Our study aims to explore the efficacy of acupuncture for depression and anxiety in IBS and to provide up-to-date evidence for clinical of IBS.

INPLASY registration number: INPLASY 202120014.

Abbreviations: AEs = adverse effects, CI = confidence interval, GRADE = Grades of Recommendation, Assessment, Development, and Evaluation, HAMA = Hamilton Anxiety, HAMD = Hamilton Depression, IBS = irritable bowel syndrome, ICTRP = International Clinical Trials Registry Platform, NIH = National Institutes of Health, PRISMA-P = Preferred reporting items for systematic reviews and meta-analysis protocols, RCTs = randomised controlled trials, RR = risk ratio, SAS = Self-Rating Anxiety Scale, SDS = Self-Rating Depression Scale, SMD = standard mean difference, WMD = weighted mean difference.

Keywords: acupuncture, anxiety, complementary therapy, depression, irritable bowel syndrome

1. Introduction

Irritable bowel syndrome (IBS) is one of the most commonly gastrointestinal diseases, and it is characterized by recurrent abdominal pain, discomfort, and altered bowel habits without any other organic disease.[1] According to patients’ bowel habits, IBS is classified into 4 main subtypes: IBS with predominant constipation (IBS-C), IBS with predominant diarrhea (IBS-D), IBS with mixed bowel habits (IBS-M), and IBS unclassified (IBS-U).[2] The Rome Foundation’s global study on 33 countries shows that the total prevalence of IBS under the Rome IV Diagnostic Criteria was 3.8% (3.6, 4.0), and the prevalence of IBS-C among women is higher than that of IBS-D, while among men this is on the contrary.[3] IBS has caused heavy pressure on individual life, health care and social economy.[4]

The pathological mechanism of IBS is complicated. It is well established that the pathogenesis of IBS is mainly related to altered visceral sensitivity,[5] brain-gut axis dysfunction,[6] intestinal dysfunction,[7] somatic and psychiatric comorbidities,[8] intestinal microbial imbalance,[9,10] and other aspects. The diversity of pathogenesis makes IBS often have other non-gastrointestinal symptoms. Many evidences indicate that most patients with IBS often have more serious psychosocial problems,[11-14] of which anxiety and depression are the most
common. These psychological disorders accompanied by IBS are closely related to the two-way regulation between the central and enteric nervous system. Long-term psychological barriers not only cause IBS patients to suffer physical and mental torture, but also face many hidden dangers such as weakening of the social labor force, reduced treatment compliance, and increased suicide risk. For IBS anxiety and depression, small doses of antidepressants and psychological treatment play a certain therapeutic role. However, due to the side effects of antidepressants, these drugs are not licensed to treat patients with IBS anywhere in the world; in contrast, in many Asian and developing countries, psychotherapy has not been effectively developed. The actual benefits of these two treatments are relatively limited.

As a traditional therapy, acupuncture has been widely used in various western medicine conditions, and it may also be a promising choice for the treatment of anxiety and depression in IBS. In recent years, a large number of studies have shown that acupuncture is effective for various types of depressive disorders. Although there are some studies on acupuncture treatment of IBS anxiety and depression, the meta-analysis of acupuncture treatment of IBS anxiety and depression is still relatively vacant. Therefore, we will conduct a meta-analysis using data from all relevant randomised controlled trials (RCTs) to comprehensively evaluate the efficacy of acupuncture in the treatment of anxiety and depression of IBS.

2. Objectives
The aims are:
1. to explore the efficacy of acupuncture for depression and anxiety in IBS and
2. to provide up-to-date evidence for clinical of IBS.

3. Methods and analysis
3.1. Study registration
The protocol of our study is conducted in strict accordance with the PRISMA-P guidelines and the Cochrane Handbook. This protocol has been registered on INPLASY (registration number: INPLASY 202120014: https://inplasy.com/inplasy-2021-2-0014/).

3.2. Inclusion criteria
3.2.1. Type of studies. All RCTs which compared acupuncture with either placebo or other drugs. RCTs conducted in adults (participants aged >16 years) without regional and language restrictions.

3.2.2. Type of participants. All patients with IBS, regardless the gender, age, race, country, and IBS type. Diagnosis of IBS based on specific diagnostic criteria (Rome I criteria, Rome II criteria, Rome III criteria, Rome IV criteria or the Manning criteria).

3.2.3. Type of interventions. The experimental group is defined as acupuncture treatment, such as body acupuncture, warm acupuncture, electro-acupuncture, auricular acupuncture, fire needling, elongated needle, or moxibustion. The control group that will include non-acupuncture techniques, such as sham acupuncture, placebo, adjuvant chemotherapy or other pharmacotherapy. The acupoint numbers, retaining time, and frequency will not be restricted in this protocol.

3.2.5. Types of outcome measures
3.2.5.1. Primary outcomes. The primary outcomes assessed will be the Hamilton Anxiety (HAMA) scale.

3.2.5.2. Secondary outcomes. Secondary outcome measures include the Self-Rating Depression Scale (SDS), the Self-Rating Anxiety Scale (SAS), the Hamilton Depression (HAMD) scale, and the rate of adverse effects (AEs).

3.3. Exclusion criteria
- Non-RCTs;
- None of the valid outcome indicators;
- Duplicated literature;
- The data used for synthesis are incomplete;
- Animal studies, case-controlled studies, cohort studies, and case reports.

3.4. Search methods for identification of studies
3.4.1. Electronic searches. RCTs of acupuncture for depression and anxiety in IBS will be searched in the relevant database, including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), and Chinese Scientific Journal Database (VIP database). The key words include “acupuncture,” “electro-acupuncture,” “warm acupuncture,” “irritable bowel syndrome,” “IBS,” “depression,” “anxiety.” An equivalent translation of the same search terms will be used to search in the Chinese databases. The search strategy of PubMed is shown in Table 1.
3.4.2. Searching other resources. We will search the National Institutes of Health (NIH) clinical registry Clinical Trials, International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov to find any potentially eligible trial data.

3.5. Selection of studies

The studies of electronic searches will be exported to EndNote V.9.1 software. Two authors will independently undertake the process of selecting the search results according to the inclusion and exclusion criteria. They will review and screen the titles and abstracts retrieved by literature search to exclude irrelevant trials. The causes of both selections will be documented and full texts will be obtained and checked for further evaluation if necessary. When there is uncertainty about eligibility of the study, reviewers will arrive at a decision by discussion and consensus with a third reviewer. The selection process will be showed in a PRISMA flow diagram (Fig. 1).

3.6. Data extraction and management

Data will be extracted independently from the selected articles by two reviewers using a Microsoft Excel spreadsheet. Information extracted from each included article will include first author, publication time, study types, characteristics of participants, type of treatments, outcome measures, and adverse events. Disagreements between reviewers in the process of data extraction were resolved by discussing with a third reviewer. Incomplete data will be provided by contacting corresponding authors.

3.7. Assessment of the methodological quality

The risk of bias for included studies will be evaluated by two reviewers using the Cochrane Collaboration’s tool for assessing
risk of bias.\textsuperscript{[27]} It includes the following seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. Any disagreement should be solved in consultation with a third reviewer.

3.8. Measures of treatment effect
Weighted mean difference (WMD) or standardized mean difference (SMD) will be adopted as statistical indicators in the analysis of continuous outcomes and the relative risk (RR) will be used to assess the treatment effect for dichotomous outcomes. Ninety-five percent of the confidence intervals (CIs) will be determined in pooled estimates.

3.9. Dealing with missing data
We will attempt to contact authors to obtain missing data. If we cannot contact the original authors, the studies will be excluded from the data synthesis.

3.10. Assessment of heterogeneity
Statistical heterogeneity should be evaluated by Chi-Squared tests and $I^2$ statistic. The results of the $I^2$ statistic, which determine the using of fixed-effects model or random-effects model, cover unimportant heterogeneity (0–40%), moderate heterogeneity (30–60%), substantial heterogeneity (50–90%), and considerable heterogeneity (75–100%). A random-effect model or subgroup analysis should be used when there exists significant heterogeneity.

3.11. Data synthesis
We will run meta-analyses using the Review Manager (RevMan) V.5.3 software. If the result of heterogeneity in $I^2 < 40\%$, the fixed-effects model will be used for data synthesis and analysis; if $I^2 \geq 40\%$ and $< 75\%$, the random-effects model will be implied; if $I^2 \geq 75\%$, it means there is considerable heterogeneity between studies. Alternatively, we will remove low-quality studies and use sensitivity analysis to investigate which study has the most significant impact on heterogeneity. If quantitative synthesis is not possible, we will make a qualitative description.

3.12. Subgroup analysis
If there is significant heterogeneity between the study results, we will perform a subgroup analysis to investigate differences in gender, age, outcome styles, etc.

3.13. Sensitivity analysis
We will perform sensitivity analyses to verify robustness of results. It includes the impact of methodological quality, study design, and sample size.

3.14. Grading the quality of evidence
Two reviewers will independently use the Grading of Recommendations Assessment, Development and Evaluation (GRADE), which evaluates the quality of evidence as “high,” “moderate,” “low,” or “very low,” to assess the quality of evidence.\textsuperscript{[28]}

3.15. Ethics and dissemination
The study will be published in a peer-reviewed journal or relevant conference. No ethical approval is required. The results of the study will provide potential guidance in advancing the therapeutic strategy of patients with IBS.

4. Discussion
Depression and anxiety are the most common non-gastrointestinal symptoms in patients with IBS. The appearance of depression and anxiety greatly increases the difficulty of treatment. Although antidepressants and psychotherapy may be beneficial for functional gastrointestinal diseases (such as IBS), adverse reactions are more common in antidepressants, especially trichloroacetic acid,\textsuperscript{[29]} and patients have limited access to psychotherapy. Therefore, more and more healthcare providers and patients turn to traditional Chinese medicine. Acupuncture is convenient and widely used for gastrointestinal diseases. Considering that no systematic analysis exists in this regard, we aimed to perform a comprehensive systematic review and meta-analysis on the efficacy of acupuncture for depression and anxiety in IBS.

Author contributions
Conceptualization: Huaiyu Li, Jing Ye.
Data curation: Huaiyu Li, Jiawang Jiang, Haiyi Tang.
Formal analysis: Yun Chen, Yuliang Zhou, Zhiying Yu.
Methodology: Yun Chen, Ziyi Hu, Haiyi Tang.
Software: Jiawang Jiang, Yuliang Zhou, Zhiying Yu.
Supervision: Jiawang Jiang, Jing Ye.
Writing – original draft: Huaiyu Li, Jiawang Jiang, Haiyi Tang.
Writing – review & editing: Jing Ye, Yuliang Zhou, Zhiying Yu.

References
\begin{thebibliography}{99}
\bibitem{1} Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA 2015;313:949–58.
\bibitem{2} Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology 2016;S0016-5085(15)3222–225.
\bibitem{3} Sperber AD, Bangdiwala SI, Droossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology 2021;160:99–114.e3.
\bibitem{4} Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 2020;17:473–86.
\bibitem{5} Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:271–93.
\bibitem{6} Gracie DJ, Hamlin PJ, Ford AC. The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. Lancet Gastroenterol Hepatol 2019;4:632–42.
\bibitem{7} Camilleri M. Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. Clin Gastroenterol Hepatol 2015;13:1051–62.
\bibitem{8} Kanuri N, Cassell B, Bruce SE, et al. The impact of abuse and mood on bowel symptoms and health-related quality of life in irritable bowel syndrome (IBS). Neurogastroenterol Motil 2016;28:1508e17.
\bibitem{9} Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017;11:196–208.
\bibitem{10} Bhattachar Y, Munir Pedroda DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol 2017;312:G52–62.
\end{thebibliography}
[11] Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006;130:1447–58.
[12] Muscatello MR, Bruno A, Mento C, et al. Personality traits and emotional patterns in irritable bowel syndrome. World J Gastroenterol 2016;22:402–15.
[13] Cho HS, Park JM, Lim CH, et al. Anxiety, depression and quality of life in patients with irritable bowel syndrome. Gut Liver 2011;5:29–36.
[14] Sugaya N, Nomura S, Shimada H. Relationship between cognitive factors and anxiety in individuals with irritable bowel syndrome. Int J Behav Med 2012;19:308–15.
[15] Lee C, Doo E, Choi JM, et al. The increased level of depression and anxiety in irritable bowel syndrome patients compared with healthy controls: systematic review and meta-analysis. J Neurogastroenterol Motil 2017;23:349–62.
[16] Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2014;264:651–60.
[17] Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2019;50:132–43.
[18] Van Oudenhove L, Crowell MD, Drossman DA, et al. Biopsychosocial aspects of functional gastrointestinal disorders. Gastroenterology 2016; S0016-5085:00218–223.
[19] Kopczynska M, Mokros L, Pietras T, et al. Quality of life and depression in patients with irritable bowel syndrome. Prz Gastroenterol 2018;13:102–8.
[20] Spiegel B, Schoenfeld P, Naliboff B. Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:183–93.
[21] Enck P, Azz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014.
[22] Zhang ZJ, Chen HY, Yip KC, et al. The effectiveness and safety of acupuncture therapy in depressive disorders: systematic review and meta-analysis. J Affect Disord 2010;124:9–21.
[23] Armour M, Smith CA, Wang LQ, et al. Acupuncture for depression: a systematic review and meta-Analysis. J Clin Med 2019;8:1140.
[24] Andreescu C, Glick RM, Emeremni CA, et al. Acupuncture for the treatment of major depressive disorder: a randomized controlled trial. J Clin Psychiatry 2011;72:1129–35.
[25] Wang H, Qi H, Wang BS, et al. Is acupuncture beneficial in depression: a meta-analysis of 8 randomized controlled trials? J Affective Disord 2008;111:125–34.
[26] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
[27] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
[28] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.
[29] Drossman DA, Tack J, Ford AC, et al. Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation Working Team Report. Gastroenterology 2018;154:1140–71.e1.